Geron Co. (NASDAQ:GERN) traded up 6.3% during trading on Friday . The company traded as high as $1.55 and last traded at $1.53, 2,261,000 shares were traded during mid-day trading. An increase of 0% from the average session volume of 2,260,143 shares. The stock had previously closed at $1.44.
A number of equities research analysts have recently commented on the company. ValuEngine raised Geron from a “hold” rating to a “buy” rating in a research note on Saturday, August 10th. B. Riley increased their target price on Geron from $3.25 to $4.50 and gave the stock a “buy” rating in a research note on Friday, June 28th. HC Wainwright assumed coverage on Geron in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $4.00 target price on the stock. BidaskClub cut Geron from a “hold” rating to a “sell” rating in a research note on Friday, September 27th. Finally, Cantor Fitzgerald assumed coverage on Geron in a research note on Thursday, August 15th. They issued an “overweight” rating and a $4.00 target price on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $3.90.
The stock has a market capitalization of $271.33 million, a PE ratio of -9.56 and a beta of 2.51. The business has a 50 day moving average price of $1.42 and a 200 day moving average price of $1.50.
Several institutional investors have recently added to or reduced their stakes in GERN. Virtus ETF Advisers LLC purchased a new stake in shares of Geron during the second quarter valued at $252,000. Vanguard Group Inc. boosted its position in shares of Geron by 1.5% during the second quarter. Vanguard Group Inc. now owns 9,644,900 shares of the biopharmaceutical company’s stock valued at $13,599,000 after buying an additional 141,384 shares during the last quarter. Creative Planning purchased a new stake in shares of Geron during the second quarter valued at $168,000. MetLife Investment Advisors LLC purchased a new stake in shares of Geron during the first quarter valued at $150,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Geron by 11.0% during the second quarter. Bank of New York Mellon Corp now owns 805,331 shares of the biopharmaceutical company’s stock valued at $1,135,000 after buying an additional 79,827 shares during the last quarter. 31.16% of the stock is currently owned by institutional investors.
About Geron (NASDAQ:GERN)
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.
Featured Article: Understanding each part of a balance sheet
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.